Latest Advances

  • Condition: Epstein-Barr Virus-Related Hemophagocytic Lymphohistiocytosis
  • Journal: Medicine
  • Treatment Used: Ruxolitinib with the HLH-94 Protocol
  • Number of Patients: 1
  • Published —
This study presents a case of a critically ill 14-year-old girl with Epstein-Barr virus-related hemophagocytic lymphohistiocytosis who was treated with Ruxolitinib in conjunction with the HLH-94 protocol.
  • Condition: SARS CoV 2 Infection in Chronic Myelogenous Leukemia
  • Journal: Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis
  • Treatment Used: Immunoglobulin, Steroids, and Antiviral Therapy
  • Number of Patients: 1
  • Published —
This case report describes a patient with COVID-19 and chronic myelogenous leukemia treated with intravenous immunoglobulin, steroids, and antiviral therapy.
  • Condition: Cytokine storm syndrome (CSS), COVID-19
  • Journal: Medicina clinica
  • Treatment Used: Glucocorticoids (GC)
  • Number of Patients: 92
  • Published —
This study compared the effects of glucocorticoids and tocilizumab versus tocilizumab alone. Researchers evaluated mortality rates, patients requiring intubation and combined amongst 92 patients who experienced a cytokine storm syndrome (CSS) associated to COVID-19.
  • Condition: Inflammatory Bowel Diseases (IBD)
  • Journal: United European gastroenterology journal
  • Treatment Used: Thiopurines
  • Number of Patients: 31
  • Published —
This study assessed the incidence and risk factors for systemic serious viral infections in patients with inflammatory bowel diseases.
  • Condition: COVID-19 with secondary hemophagocytic lymphohistocytosis
  • Journal: Cell host & microbe
  • Treatment Used: Anakinra
  • Number of Patients: 8
  • Published —
The study researched the use of Anakinra for patients with COVID-19 with secondary hemophagocytic lymphohistocytosis.
  • Condition: COVID-19 Infection-Induced Cytokine Release Syndrome (CRS)
  • Journal: Chest
  • Treatment Used: Tocilizumab
  • Number of Patients: 2
  • Published —
This study evaluated the effectiveness of tocilizumab in patients with COVID-19 (a mild to severe respiratory illness that is caused by a coronavirus) infection-induced cytokine release syndrome (large, rapid release of cytokines into the blood from immune cells affected by the immunotherapy; CRS).
  • Condition: Relapsed/Refractory Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis
  • Journal: Blood
  • Treatment Used: Nivolumab
  • Number of Patients: 7
  • Published —
This analysis reviewed patients with relapsed/refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis who were treated with nivolumab.
  • Condition: Acute Graft-versus-host Disease
  • Journal: Annals of hematology
  • Treatment Used: Ruxolitinib
  • Number of Patients: 12
  • Published —
In this study, researchers evaluated the effects of using ruxolitinib to treat acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation in patients with Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
  • Condition: Epstein-Barr Virus-associated Hemophagocytic Lymphohistiocytosis
  • Journal: British journal of haematology
  • Treatment Used: Etoposide
  • Number of Patients: 93
  • Published —
In this study, researchers evaluated the effects of etoposide on Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis.
  • Condition: Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis (HLH)
  • Journal: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
  • Treatment Used: Fludarabine/Melphalan 100 mg/m2 Conditioning Therapy Followed by Allogeneic Hematopoietic Cell Transplantation (HCT)
  • Number of Patients: 16
  • Published —
This study evaluated the reduced-intensity conditioning regimen in allogeneic hematopoietic cell transplantation (HCT) for adult patients with hemophagocytic lymphohistiocytosis (too many immune cells; HLH).
  • Condition: Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis (EBV-HLH) in Adults and Adolescents
  • Journal: Hematology (Amsterdam, Netherlands)
  • Treatment Used: DEP/L-DEP, HLH-94/04, allo-HSCT
  • Number of Patients: 133
  • Published —
This study evaluated the clinical manifestation and the effects and prognosis of existing regimens of Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis (EBV-HLH) in adult and adolescents.
Showing 1-11 of 11